Sarah Hayat, MD
Critical Care Medicine · Lawrenceville, GANPI 1780865527
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by GSK at 24.3% of the total. 2025 is the largest year on record at $1,440, 5.8 times the $249 reported in 2019.
Across 143 payments — averaging $24.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$841
- Insmed, Inc.$398
- AstraZeneca$281
- Merck$281
- Boehringer Ingelheim$253
- Sanofi$236
- plus $1K from 18 others
Across 1 payment — averaging $2800.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$3K
What the payments were for
- Food & beverage$3,43899%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 52 | $841 |
| Insmed, Inc. | 14 | $398 |
| AstraZeneca | 10 | $281 |
| Merck | 10 | $281 |
| Boehringer Ingelheim | 5 | $253 |
| Sanofi | 9 | $236 |
| Regeneron Healthcare Solutions, Inc. | 8 | $200 |
| United Therapeutics Corporation | 5 | $175 |
| Johnson & Johnson | 2 | $159 |
| Actelion Pharmaceuticals US, Inc. | 2 | $134 |
| Amgen | 3 | $79 |
| Pfizer | 4 | $76 |
| Mylan Specialty L.p. | 3 | $58 |
| Novo Nordisk | 1 | $49 |
| Harmony Biosciences LLC | 2 | $48 |
| Novartis | 2 | $34 |
| Resmed Corp | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 3 | $28 |
| Pulmonx Corporation | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Verona Pharma, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Philips North America LLC | 1 | $15 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,467 in reported general payments places this provider in the 80th percentile of 265 critical care medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 681 | $566,916 |
| OfevNintedanib Esylate | 41 | $526,183 |
| NucalaMepolizumab | 111 | $439,225 |
| OpsumitMacitentan | 23 | $291,368 |
| Breo ElliptaFluticasone/Vilanterol | 451 | $237,656 |
| Dupixent PenDupilumab | 24 | $91,995 |
| Fasenra PenBenralizumab | 15 | $82,086 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 82 | $67,185 |
| EliquisApixaban | 56 | $56,586 |
| XareltoRivaroxaban | 53 | $50,693 |
| Orenitram ErTreprostinil Diolamine | 12 | $40,749 |
| Spiriva RespimatTiotropium Bromide | 60 | $39,615 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 281 | $38,780 |
| Advair HfaFluticasone Propion/Salmeterol | 71 | $29,251 |
| SymbicortBudesonide/Formoterol Fumarate | 74 | $27,618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $841 | $1,318,7691,466 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $253 | $582,374118 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $134 | $291,36823 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $281 | $94,804156 claims |
| PfizerEliquis | $76 | $56,58656 claims |
| Johnson & JohnsonXarelto | $159 | $50,69353 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 265 critical care medicine providers in Georgia.
Other critical care medicine in Lawrenceville
- Rajesh JasaniLawrenceville$8K
- Paul WeinbergLawrenceville$6K
- Lawrence KaplanLawrenceville$4K
- William McGannLawrenceville$3K
- Salman FidahusseinLagrange$852K
- Bruce FriedmanAugusta$629K
- Gregory MauldinSnellville$221K
- Ramzy RimawiAtlanta$72K
- Rafael Alba YunenBrunswick$58K
- April McDonaldGainesville$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.